Factor VIIa binding to endothelial cell protein C receptor protects vascular barrier integrity in vivo

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 5, 2014, Pages 690-700

  Sundaram, J ^a   Keshava, S ^a   Gopalakrishnan, R ^a   Esmon, C T ^b   Pendurthi, U R ^a   Rao, L V M ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Activated protein C receptor; Capillary permeability; Factor VIIa; Hemophilia A; Protein C

Indexed keywords

BLOOD CLOTTING FACTOR 7A; ENDOTHELIAL PROTEIN C RECEPTOR; LIPOPOLYSACCHARIDE; THROMBIN; VASCULOTROPIN; ACTIVATED PROTEIN C RECEPTOR; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; CELL SURFACE RECEPTOR; PROTEIN BINDING; PROTEIN C; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG BINDING; ENDOTHELIUM CELL; FEMALE; HEMOPHILIA A; IN VIVO STUDY; KIDNEY DISEASE; KIDNEY VASCULAR LEAKAGE; LOW DRUG DOSE; LUNG VASCULAR LEAKAGE; MALE; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; SKIN DISEASE; SKIN VASCULAR LEAKAGE; ANIMAL; C57BL MOUSE; CAPILLARY PERMEABILITY; CELL CULTURE; CHEMISTRY; CYTOLOGY; GENOTYPE; HUMAN; METABOLISM; PERMEABILITY; TRANSGENIC MOUSE;

ANIMALS; BLOOD COAGULATION FACTORS; CAPILLARY PERMEABILITY; CELLS, CULTURED; ENDOTHELIAL CELLS; FACTOR VIIA; FACTOR XA; FEMALE; GENOTYPE; HEMOPHILIA A; HUMANS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PERMEABILITY; PROTEIN BINDING; PROTEIN C; RECEPTORS, CELL SURFACE; THROMBIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901197891     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12532     Document Type: Article

References (31)

1. Ghosh S, Pendurthi UR, Steinoe A, Esmon CT, Rao LV. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem 2007; 282: 11849-57.
2. Nayak RC, Sen P, Ghosh S, Gopalakrishnan R, Esmon CT, Pendurthi UR, Rao LVM. Endothelial cell protein C receptor cellular localization and trafficking. Blood 2009; 114: 1974-86.
3. Preston RJ, Ajzner E, Razzari C, Karageorgi S, Dua S, Dahlback B, Lane DA. Multifunctional specificity of the protein C/activated protein C Gla domain. J Biol Chem 2006; 281: 28850-7.
4. Lopez-Sagaseta J, Montes R, Puy C, Diez N, Fukudome K, Hermida J. Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity. J Thromb Haemost 2007; 5: 1817-24.
5. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by protein C pathway. Science 2002; 296: 1880-2.
6. Burnier L, Mosnier LO. Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3. Blood 2013; 122: 807-16.
7. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105: 3178-84.
8. Sen P, Gopalakrishan R, Kothari H, Keshava S, Clark C, Esmon CT, Pendurthi UR, Rao LVM. Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection. Blood 2011; 117: 3199-208.
9. Schuepbach RA, Feistritzer C, Fernandez JA, Griffin JH, Riewald M. Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thromb Haemost 2009; 101: 724-33.
10. Schuepbach RA, Riewald M. Coagulation factor Xa cleaves PAR1 and mediates signaling dependent on binding to the endothelial protein C receptor. J Thromb Haemost 2010; 8: 379-88.
11. Clark CA, Vatsyayan R, Hedner U, Esmon CT, Pendurthi UR, Rao LV. Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa. J Thromb Haemost 2012; 10: 2383-91.
12. Li W, Zheng X, Gu J, Hunter J, Ferrell GL, Lupu F, Esmon NL, Esmon CT. Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost 2005; 3: 1351-9.
13. Li W, Zheng X, Gu JM, Ferrell GL, Brady M, Esmon NL, Esmon CT. Extraembryonic expression of EPCR is essential for embryonic viability. Blood 2005; 106: 2716-22.
14. Bae JS, Kim YU, Park MK, Rezaie AR. Concentration dependent dual effect of thrombin in endothelial cells via Par-1 and Pi3 Kinase. J Cell Physiol 2009; 219: 744-51.
15. Di Serio C, Pellerito S, Duarte M, Massi D, Naldini A, Cirino G, Prudovsky I, Santucci M, Geppetti P, Marchionni N, Masotti G, Tarantini F. Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism. Basic Clin Pharmacol Toxicol 2007; 101: 63-9.
16. von Drygalski A, Furlan-Freguia C, Ruf W, Griffin JH, Mosnier LO. Organ-specific protection against lipopolysaccharide-induced vascular leak is dependent on the endothelial protein C receptor. Arterioscler Thromb Vasc Biol 2013; 33: 769-76.
17. Petersen LC, Elm T, Ezban M, Krogh TN, Karpf DM, Steino A, Olsen EH, Sorensen BB. Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors. Thromb Haemost 2009; 101: 818-26.
18. Zhong Z, Ilieva H, Hallagan L, Bell R, Singh I, Paquette N, Thiyagarajan M, Deane R, Fernandez JA, Lane S, Zlokovic AB, Liu T, Griffin JH, Chow N, Castellino FJ, Stojanovic K, Cleveland DW, Zlokovic BV. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest 2009; 119: 3437-49.
19. Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 2007; 110: 3909-16.
20. Bae JS, Yang L, Rezaie AR. Factor X/Xa elicits protective signaling responses in endothelial cells directly via PAR-2 and indirectly via endothelial protein C receptor-dependent recruitment of PAR-1. J Biol Chem 2010; 285: 34803-12.
21. Mosnier LO, Sinha RK, Burnier L, Bouwens EA, Griffin JH. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood 2012; 120: 5237-46.
22. Neri Serneri GG, Gensini GF, Gensini RA. Increased capillary permeability in haemophilia and afibrinogenaemia. Acta Haematol 1974; 52: 336-44.
23. O'Doherty MJ, Page CJ, Harrington C, Nunan T, Savidge G. Haemophilia, AIDS and lung epithelial permeability. Eur J Haematol 1990; 44: 252-6.
24. Corada M, Mariotti M, Thurston G, Smith K, Kunkel R, Brockhaus M, Lampugnani MG, Martin-Padura I, Stoppacciaro A, Ruco L, Mcdonald DM, Ward PA, Dejana E. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci USA 1999; 96: 9815-20.
25. Hatakeyama K, Yano S, Watanabe K. Gastric bleeding and increased gastric vascular permeability induced by platelet activating factor (PAF): effect of drugs that affect arachidonate metabolism. Jpn J Pharmacol 1991; 56: 271-7.
26. Goldenberg NM, Steinberg BE, Slutsky AS, Lee WL. Broken barriers: a new take on sepsis pathogenesis. Sci Transl Med 2011; 3: 88ps25.
27. Stevens T, Garcia JG, Shasby DM, Bhattacharya J, Malik AB. Mechanisms regulating endothelial cell barrier function. Am J Physiol Lung Cell Mol Physiol 2000; 279: L419-22.
28. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 2008; 100: 557-62.
29. Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology Am Soc Hematol Educ Program 2010; 2010: 153-9.
30. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011; 154: 529-40.
31. Stein DM, Dutton RP, Hess JR, Scalea TM. Low-dose recombinant factor VIIa for trauma patients with coagulopathy. Injury 2008; 39: 1054-61.